Citadel Advisors
TTNP

Citadel Advisors’s Titan Pharmaceuticals TTNP Stock Holding History

Citadel Advisors’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,069
Closed -$50.7K – 14147
2025
Q2 		$50.7K Buy
12,069
+108
+0.9% +$458 ﹤0.01% 11762
2025
Q1 		$42.2K Buy
+11,961
New +$43.1K ﹤0.01% 12485
2023
Q3 		– Sell
-1,484
Closed -$19.2K – 15135
2023
Q2 		$19.2K Buy
+1,484
New +$22.7K ﹤0.01% 12757
2022
Q4 		– Sell
-654
Closed -$14K – 15468
2022
Q3 		$14K Buy
+654
New +$16.9K ﹤0.01% 12184
2021
Q3 		– Sell
-3,445
Closed -$151K – 14673
2021
Q2 		$179K Buy
3,445
+2,481
+257% +$124K ﹤0.01% 12292
2021
Q1 		$57K Sell
964
-162
-14% -$10.7K ﹤0.01% 12840
2020
Q4 		$74K Buy
1,126
+848
+305% +$67K ﹤0.01% 10390
2020
Q3 		$28K Buy
278
+6
+2% +$926 ﹤0.01% 9786
2020
Q2 		$50K Buy
+272
New +$46.8K ﹤0.01% 9306
2019
Q1 		– Sell
-23
Closed -$22.3K – 9868
2018
Q4 		$18K Buy
+23
New +$25.8K ﹤0.01% 8790
2018
Q2 		– Sell
-10
Closed -$39K – 9301
2018
Q1 		$39K Buy
+10
New +$41.8K ﹤0.01% 7992
2016
Q3 		– Sell
-4
Closed -$85K – 7789
2016
Q2 		$85K Buy
+4
New +$85.2K ﹤0.01% 6259

Other funds holding TTNP

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GWSA
Global Wealth Strategies & Associates Denver, Colorado $528M AUM 23.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors's TTNP Position: Q3 2025 in Review

Citadel Advisors sold out of Titan Pharmaceuticals (TTNP) in Q3 2025, closing a stake of 12,069 shares — an estimated $50.7K sold.

Citadel Advisors first reported a position in TTNP in Q2 2016 and held it in 12 quarters. The position peaked at $179K in Q2 2021. 18 funds tracked by Wall St. Rank hold TTNP as of Q3 2025.

  • Citadel Advisors reported no remaining Titan Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Citadel Advisors sold 12,069 Titan Pharmaceuticals shares in Q3 2025, an estimated $50.7K.
  • Citadel Advisors first reported a position in Titan Pharmaceuticals in Q2 2016 and held it in 12 quarters.
  • Citadel Advisors's Titan Pharmaceuticals position peaked at $179K in Q2 2021.
  • 18 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.